Literature DB >> 23091290

Dosimetric advantages of generalised equivalent uniform dose-based optimisation on dose-volume objectives in intensity-modulated radiotherapy planning for bilateral breast cancer.

T-F Lee1, H-M Ting, P-J Chao, H-Y Wang, C-S Shieh, M-F Horng, J-M Wu, S-A Yeh, M-Y Cho, E-Y Huang, Y-J Huang, H-C Chen, F-M Fang.   

Abstract

OBJECTIVE: We compared and evaluated the differences between two models for treating bilateral breast cancer (BBC): (i) dose-volume-based intensity-modulated radiation treatment (DV plan), and (ii) dose-volume-based intensity-modulated radiotherapy with generalised equivalent uniform dose-based optimisation (DV-gEUD plan).
METHODS: The quality and performance of the DV plan and DV-gEUD plan using the Pinnacle(3) system (Philips, Fitchburg, WI) were evaluated and compared in 10 patients with stage T2-T4 BBC. The plans were delivered on a Varian 21EX linear accelerator (Varian Medical Systems, Milpitas, CA) equipped with a Millennium 120 leaf multileaf collimator (Varian Medical Systems). The parameters analysed included the conformity index, homogeneity index, tumour control probability of the planning target volume (PTV), the volumes V(20 Gy) and V(30 Gy) of the organs at risk (OAR, including the heart and lungs), mean dose and the normal tissue complication probability.
RESULTS: Both plans met the requirements for the coverage of PTV with similar conformity and homogeneity indices. However, the DV-gEUD plan had the advantage of dose sparing for OAR: the mean doses of the heart and lungs, lung V(20) (Gy), and heart V(30) (Gy) in the DV-gEUD plan were lower than those in the DV plan (p<0.05).
CONCLUSIONS: A better result can be obtained by starting with a DV-generated plan and then improving it by adding gEUD-based improvements to reduce the number of iterations and to improve the optimum dose distribution. Advances to knowledge The DV-gEUD plan provided superior dosimetric results for treating BBC in terms of PTV coverage and OAR sparing than the DV plan, without sacrificing the homogeneity of dose distribution in the PTV.

Entities:  

Mesh:

Year:  2012        PMID: 23091290      PMCID: PMC3500793          DOI: 10.1259/bjr/24112047

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  31 in total

1.  IMRT for breast. a planning study.

Authors:  A Fogliata; G Nicolini; M Alber; M Asell; B Dobler; M El-Haddad; B Hårdemark; U Jelen; A Kania; M Larsson; F Lohr; T Munger; E Negri; C Rodrigues; L Cozzi
Journal:  Radiother Oncol       Date:  2005-09       Impact factor: 6.280

2.  Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.

Authors:  Ellen D Yorke; Andrew Jackson; Kenneth E Rosenzweig; Louise Braban; Steven A Leibel; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-04       Impact factor: 7.038

Review 3.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

4.  Long-term cardiac mortality after radiotherapy of breast cancer--application of the relative seriality model.

Authors:  G Gagliardi; I Lax; A Ottolenghi; L E Rutqvist
Journal:  Br J Radiol       Date:  1996-09       Impact factor: 3.039

5.  Cardiac disease following treatment of Hodgkin's disease in children and adolescents.

Authors:  S L Hancock; S S Donaldson; R T Hoppe
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

6.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

7.  A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319.

Authors:  Frank Vicini; Kathryn Winter; William Straube; John Wong; Helen Pass; Rachel Rabinovitch; Susan Chafe; Douglas Arthur; Ivy Petersen; Beryl McCormick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-29       Impact factor: 7.038

8.  Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma.

Authors:  S V Gollamudi; R S Gelman; G Peiro; L J Schneider; S J Schnitt; A Recht; B J Silver; J R Harris; J L Connolly
Journal:  Cancer       Date:  1997-04-01       Impact factor: 6.860

9.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)

Authors:  M V Graham; J A Purdy; B Emami; W Harms; W Bosch; M A Lockett; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-09-01       Impact factor: 7.038

10.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

View more
  6 in total

1.  Volumetric modulated arc therapy for synchronous bilateral whole breast irradiation - A case study.

Authors:  Jan Seppälä; Janne Heikkilä; Kimmo Myllyoja; Kristiina Koskela
Journal:  Rep Pract Oncol Radiother       Date:  2015-06-15

2.  Initial evaluation of automated treatment planning software.

Authors:  Dawn Gintz; Kujtim Latifi; Jimmy Caudell; Benjamin Nelms; Geoffrey Zhang; Eduardo Moros; Vladimir Feygelman
Journal:  J Appl Clin Med Phys       Date:  2016-05-08       Impact factor: 2.102

3.  Radial Data Mining to Identify Density-Dose Interactions That Predict Distant Failure Following SABR.

Authors:  Angela Davey; Marcel van Herk; Corinne Faivre-Finn; Alan McWilliam
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

4.  Efficacy, safety, and feasibility of volumetric modulated arc therapy for synchronous bilateral breast cancer management.

Authors:  Stanislas Quesada; Pascal Fenoglietto; Sophie Gourgou; Claire Lemanski; Roxana Draghici; Norbert Ailleres; Jessica Prunaretty; David Azria; Céline Bourgier
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

5.  A quantitative analysis of intensity-modulated radiation therapy plans and comparison of homogeneity indices for the treatment of gynecological cancers.

Authors:  Pushpraj Pathak; Sanjeev Vashisht
Journal:  J Med Phys       Date:  2013-04

6.  On the gEUD biological optimization objective for organs at risk in Photon Optimizer of Eclipse treatment planning system.

Authors:  Antonella Fogliata; Stephen Thompson; Antonella Stravato; Stefano Tomatis; Marta Scorsetti; Luca Cozzi
Journal:  J Appl Clin Med Phys       Date:  2017-11-20       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.